NewMediaWire distributes press releases on behalf of hundreds of publicly traded companies, as well as private corporations, non-profits and other public sector organizations. Founded and staffed by industry veterans, we offer a full complement of services including specialized delivery to financial sites and posting of photos and multimedia content. In addition, NewMediawire offers international and specialized services such as IR websites and industry specific distribution.
November 17, 2024 — Research Highlights: Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and blood clot prevention in patients after heart valve replacement surgery as warfarin, the current standard treatment. Unlike warfarin, edoxaban does not require regular blood tests to monitor clotting activity and does not interact with food or other medications, which simplifies treatment for patients, researchers noted.
November 17, 2024 — Research Highlights: The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries involving bypass did not result in significant benefits at preventing death, stroke or organ injury compared to a placebo. Researchers noted, however, additional research is needed to determine if there are any benefits from other GLP-1 medications or from administration of exenatide for a longer period of time or at a larger dose than was tested in this study.
November 16, 2024 — Research Highlights: A new software program that uses artificial intelligence to read echocardiograms may reduce the wait times for results and lead to more timely medical care. PanEcho is the first AI system to automatically assess all key areas of heart health from echocardiograms with images from multiple views and identify which views are most relevant for each imaging task.
November 16, 2024 — Research Highlights: Pharmacists in the Veterans Health Administration System who received feedback on their patients’ heart failure medication rates, along with educational tools and targeted information, had a significant increase in the frequency at which they managed heart failure and adjusted heart failure medications in their patient populations. Providing primary care pharmacists with real-time feedback is a practical intervention that could improve heart failure and chronic disease management, the researchers noted.
November 16, 2024 — Research Highlights: In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline, stroke or transient ischemic attack (TIA) in people younger than age 65 who had atrial fibrillation (AFib) but no other stroke risk factors. AFib is the most common type of irregular heart rhythm in the U.
November 16, 2024 — Research Highlights: A new, multicenter study demonstrated that ablation treatment may be a better first option than medication for many heart attack survivors who develop abnormal electrical short circuits in their heart, which are episodes of dangerous rapid heart rhythms that can lead to fainting, heart failure or cardiac arrest. Currently, there are two main types of treatments used to prevent rapid heart rhythms: medications, which are usually used first, and if those fail, then a minimally invasive procedure called catheter ablation, in which the abnormal electrical circuits are cauterized.
November 16, 2024 — Research Highlights: A study of almost 13,000 adults with Type 2 diabetes and high systolic blood pressure assessed if a more intensive treatment approach with a lower blood pressure goal would decrease the risk of major cardiovascular events, including non-fatal heart attacks, strokes and hospitalized heart failure, or death due to cardiovascular disease. In the Blood Pressure Control Target in Diabetes (BPROAD) Study in China, approximately half of the trial participants received more aggressive treatment to lower their systolic blood pressure to less than 120 mm Hg, and the other half received treatment to lower their systolic blood pressure to less than 140 mm Hg.
November 15, 2024 — SAN FRANCISCO - (NewMediaWire) - November 15, 2024 - PACS Group, Inc. (NYSE: PACS) and certain of its key executives have been named as defendants in a securities class action brought on behalf of PACS investors alleging violations of the U.
November 15, 2024 — WMU Athletics & Broncos Will Reign Collective Partner With Roy, Empowering Fans to Support All WMU Athletes Directly via NIL App MINNEAPOLIS, Minn. - (NewMediaWire) - November 15, 2024 - Western Michigan University Athletics and the Broncos Will Reign Collective are excited to announce a new partnership with Roy, Inc.
November 14, 2024 — SAN FRANCISCO - (NewMediaWire) - November 14, 2024 - Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb.
November 14, 2024 — SAN FRANCISCO - (NewMediaWire) - November 14, 2024 - Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) announced that it would not timely file its quarterly report with the Securities and Exchange Commission because of its pending investigations into the company’s sales practices.
November 14, 2024 — SAN FRANCISCO - (NewMediaWire) - November 14, 2024 - Acadia Healthcare Company (NASDAQ: ACHC) is facing securities class action lawsuits by investors alleging the company misled them about its business practices. The more recent lawsuit filed on October 29, 2024 expanded the Class Period to end on Oct.
November 14, 2024 — ● ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. ● Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in income● Received Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024FREMONT, Calif.
November 14, 2024 — OCOEE, Fla. - (NewMediaWire) - November 14, 2024 - iCoreConnect Inc (NASDAQ: ICCT) (“iCore” or the “Company”), a leading provider of cloud-based software and technology solutions, has announced a new endorsement agreement with the North Dakota Dental Association (NDDA).
November 14, 2024 — TORONTO, Ontario - (NewMediaWire) - November 14, 2024 - ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, announces financial results for the third quarter ended September 30, 2024, and provides highlights from the quarter.
